Metasedin (Methadone Hydrochloride)

Methadone hydrochloride is a full agonist at mu‑opioid receptors in the central nervous system. By activating these receptors, it mimics the effects of natural opioids, producing analgesia and suppressing the neuro‑chemical pathways that trigger opioid withdrawal, thereby reducing cravings and stabilizing pain perception.

The dose of Metasedin is individualized. A qualified prescriber determines the appropriate amount based on the patient’s clinical condition, prior opioid exposure, and response to therapy. Dosing may be adjusted over time to achieve optimal control of withdrawal symptoms or pain.

Safety data for methadone in pregnancy and lactation are limited. Methadone may be used when the benefits outweigh potential risks, but it can cross the placenta and appear in breast milk. Clinicians should assess each case carefully and monitor both mother and infant closely.

To order Metasedin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both methadone (Metasedin) and buprenorphine are used for opioid dependence, but methadone is a full mu‑opioid agonist offering stronger analgesia, while buprenorphine is a partial agonist with a ceiling effect on respiratory depression. Choice depends on patient history, treatment setting, and risk‑benefit considerations.

Metasedin should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Metasedin is taken orally, usually as a tablet or oral solution, according to the prescriber’s instructions. It should be swallowed whole with water and not crushed or chewed unless specifically directed by a healthcare professional.

The most serious risks include respiratory depression, especially when combined with other CNS depressants, and cardiac arrhythmias due to QT‑interval prolongation. Patients should be monitored for signs of overdose, severe sedation, or irregular heart rhythms, and emergency care sought if these occur.

Metasedin is contraindicated in individuals with known hypersensitivity to methadone, those with severe respiratory insufficiency, uncontrolled cardiac arrhythmias, or significant QT prolongation. It should also be avoided in patients taking strong CYP3A4 inhibitors without close medical supervision.